ACS Applied Materials & Interfaces · 2017 · 164 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCombination Cancer TherapyCombination ChemotherapyCytotoxic ChemotherapyControlled ReleaseControlled Release MaterialsHost-guest ComplexationHost-guest Inclusion ComplexationHost-guest RelationsOxaliplatin-based TherapySupramolecular Encapsulation
Supramolecular chemotherapy is aimed to employ supramolecular approach for regulating the cytotoxicity and improving the efficiency of antitumor drugs. In this paper, we demonstrated a new example of supramolecular chemotherapy by utilizing the clinical antitumor drug, oxaliplatin, which is the specific drug for colorectal cancer treatment. Cytotoxicity of oxaliplatin to the colorectal normal cell could be significantly decreased by host-guest complexation between oxaliplatin and cucurbit[7]uril (CB[7]). More importantly, oxaliplatin-CB[7] exhibited cooperatively enhanced antitumor activity than oxaliplatin itself. On the one hand, the antitumor activity of oxaliplatin can reappear by competitive replacement of spermine from oxaliplatin-CB[7]; on the other hand, CB[7] can consume the overexpressed spermine in tumor environments, which is essential for tumor cell growth. These two events can lead to the cooperatively enhanced antitumor performance. Supramolecular chemotherapy can be applied to treat with spermine-overexpressed tumors. It is highly anticipated that this strategy may be employed in many other clinical antitumor drugs, which opens a new horizon of supramolecular chemotherapy for potential applications in clinical antitumor treatments.
24
Jaheon Kim, In‐Sun Jung, Sooyoung Kim et al. · Journal of the American Chemical Society · 2000 · 1.7K citations
Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies
Amy B. Knudsen, Ann G. Zauber, Carolyn M. Rutter et al. · JAMA · 2016 · 485 citations · Full text